Stellanova Therapeutics is developing the first cancer therapies targeting cancer-associated fibroblasts (CAFs) and their symbiotic interactions within the tumor microenvironment. The company was founded based on research out of Dr. Rosa Hwang’s lab at MD Anderson Cancer Center demonstrating that targeting factors produced by stellate cells, a star-shaped subtype of CAFs present in pancreatic cancer, have the potential to both directly combat cancer and make tumor cells more vulnerable to traditional therapeutic approaches, including chemotherapy and immunotherapy. Stellanova means “new star”, and it is the company’s goal to establish an entirely new approach to treating cancer.
Company Details
- Employees
- 2
- Address
- 2450 Holcombe Blvd, Houston,tx 77021,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://stellanovatx.com
- HQ
- Houston, TX
Stellanova Therapeutics Questions
Stellanova Therapeutics's website is https://stellanovatx.com
Stellanova Therapeutics's LinkedIn profile is https://www.linkedin.com/company/stellanovatx
Stellanova Therapeutics has
2 employees.
View email and phone details for 2
employees at Stellanova Therapeutics.
Stellanova Therapeutics's industry is
Biotechnology Research
Stellanova Therapeutics's top competitors are
Immunogenesis, Inc.,
Lindonlight Collective,
Celltex Therapeutics Corporation,
Texas Biotechnology Inc.,
Sporos Bioventures,
Kiromic Biopharma, Inc.,
Salarius Pharmaceuticals,
Polyscitech Division: Akina, Inc.,
Innovative Biochips, Llc,
Flare Therapeutics.
Stellanova Therapeutics's categories are Biotechnology Research
